MedTrace Logo

Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease

NCT00573547 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2011-08-16

No results posted yet for this study

Summary

The purpose of this study is to test whether once-weekly prozac therapy leads to reduction in depression in patients requiring kidney dialysis.

Conditions

Interventions

DRUG

Fluoxetine

Fluoxetine will be dosed at 90 mg once a week

Sponsors & Collaborators

  • Creighton University

    lead OTHER

Principal Investigators

  • Syed P Sattar, MD · Creighton University Department of Psychiatry

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00573547 on ClinicalTrials.gov